​

Moderna (MRNA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MRNA Stock Forecast

Moderna (MRNA) stock forecast, based on 26 Wall Street analysts, predicts a 12-month average price target of $104.90, with a high of $238.00 and a low of $55.00. This represents a 157.61% increase from the last price of $40.72.

- $50 $100 $150 $200 $250 High: $238 Avg: $104.9 Low: $55 Last Closed Price: $40.72

MRNA Stock Rating

Moderna stock's rating consensus is Hold, based on 26 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (38.46%), 14 Hold (53.85%), 2 Sell (7.69%), and 0 Strong Sell (0.00%).

Hold
Total 26 2 14 10 0 Strong Sell Sell Hold Buy Strong Buy

MRNA Forecast vs Benchmarks

TypeNameUpside
StockModerna157.61%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-233
Avg Price Target-$63.50$123.61
Last Closing Price$40.72$40.72$40.72
Upside/Downside-55.94%203.56%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2536151328
Dec, 2436151328
Nov, 2437152229
Oct, 2437152229
Sep, 2438153231
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 18, 2024Edward TenthoffPiper Sandler$69.00$37.2785.14%69.45%
Nov 18, 2024Yifeng LiuHSBC$58.00$84.93-31.71%42.44%
Oct 17, 2024Courtney BreenBernstein$55.00$57.46-4.28%35.07%
Oct 14, 2024Michael YeeJefferies$55.00$57.73-4.73%35.07%
Sep 13, 2024Edward TenthoffPiper Sandler$115.00$69.6865.04%182.42%
Sep 13, 2024Luca IssiRBC Capital$75.00$69.687.63%84.18%
Sep 13, 2024Leah Rush CannLoop Capital Markets$238.00$69.68241.56%484.48%
Sep 12, 2024Michael YeeJefferies$65.00$69.68-6.72%59.63%
Sep 12, 2024Cory KasimovEvercore ISI$105.00$67.6855.14%157.86%
Sep 12, 2024Matthew HarrisonMorgan Stanley$94.00$67.5139.24%130.84%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Dec 11, 2024Evercore ISIReducedowngrade
Dec 10, 2024HSBCHoldBuyupgrade
Nov 22, 2024JefferiesHoldHoldhold
Nov 18, 2024Piper SandlerOverweightOverweighthold
Oct 24, 2024Piper SandlerOverweightOverweighthold
Oct 21, 2024Cowen & Co.HoldHoldhold
Oct 17, 2024BernsteinMarket Performinitialise
Oct 15, 2024Sandler O'NeilUnderperformUnderperformhold
Oct 14, 2024JefferiesHoldHoldhold
Sep 13, 2024Sandler O'NeillSector PerformSector Performhold

Financial Forecast

EPS Forecast

$-20 $-9 $2 $13 $24 $35 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.96$30.28$21.22$-12.34-----
Avg Forecast$-1.57$27.27$21.26$-13.46$-9.12$-8.91$-6.91$-4.90$-2.64
High Forecast$-1.96$22.35$17.34$-15.66$-10.29$-10.29$-8.49$-7.46$-3.35
Low Forecast$-1.29$34.01$25.98$-11.27$-8.03$-6.72$-2.06$1.34$-1.89
Surprise %24.84%11.04%-0.19%-8.32%-----

Revenue Forecast

$0 $5B $10B $15B $20B $25B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$274.49M$17.74B$19.26B$6.85B-----
Avg Forecast$534.89M$18.02B$19.13B$6.47B$3.23B$2.56B$3.09B$4.14B$5.30B
High Forecast$460.65M$15.52B$16.42B$6.17B$3.15B$2.27B$3.02B$4.01B$4.14B
Low Forecast$636.62M$21.45B$22.40B$6.84B$3.35B$3.16B$3.16B$4.27B$6.40B
Surprise %-48.68%-1.57%0.70%5.92%-----

Net Income Forecast

$-10B $-4B $2B $8B $14B $20B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-747.06M$12.20B$8.36B$-4.71B-----
Avg Forecast$-607.66M$11.55B$13.15B$-4.71B$-3.50B$-3.53B$-2.71B$-1.97B$-1.01B
High Forecast$-729.20M$9.24B$10.52B$-5.66B$-3.93B$-3.93B$-3.24B$-2.85B$-1.28B
Low Forecast$-486.13M$13.86B$15.78B$-3.77B$-3.07B$-2.57B$-787.35M$510.78M$-721.88M
Surprise %22.94%5.65%-36.42%------

MRNA Forecast FAQ

Is Moderna stock a buy?

Moderna stock has a consensus rating of Hold, based on 26 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 14 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Moderna is a neutral investment for most analysts.

What is Moderna's price target?

Moderna's price target, set by 26 Wall Street analysts, averages $104.9 over the next 12 months. The price target range spans from $55 at the low end to $238 at the high end, suggesting a potential 157.61% change from the previous close price of $40.72.

How does Moderna stock forecast compare to the average forecast of its sector, industry, and investment themes?

Moderna stock forecast shows a 157.61% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Moderna over the past three months?

  • January 2025: 10.71% Strong Buy, 21.43% Buy, 53.57% Hold, 3.57% Sell, 10.71% Strong Sell.
  • December 2024: 10.71% Strong Buy, 21.43% Buy, 53.57% Hold, 3.57% Sell, 10.71% Strong Sell.
  • November 2024: 10.34% Strong Buy, 24.14% Buy, 51.72% Hold, 6.90% Sell, 6.90% Strong Sell.

What is Moderna’s EPS forecast?

Moderna's average annual EPS forecast for its fiscal year ending in December is -9.12 for 2024, a -26.09% decrease from the reported $-12.34 in 2023. The prediction for 2025 is $-8.91, $-6.91 for 2026, $-4.9 for 2027, and $-2.64 for 2028.

What is Moderna’s revenue forecast?

Moderna's average annual revenue forecast for its fiscal year ending in December is $3.23B for 2024, a -52.89% decrease from the reported $6.85B in 2023. The forecast for 2025 is $2.56B, $3.09B for 2026, $4.14B for 2027, and $5.3B for 2028.

What is Moderna’s net income forecast?

For its fiscal year ending in December, Moderna's average annual net income forecast is $-3.498B for 2024, reflecting a -25.79% decrease from the reported $-4.714B in 2023. The projection for 2025 is $-3.53B, $-2.713B for 2026, $-1.966B for 2027, and $-1.01B for 2028.